Efficacy of Administration of ACE-Inhibition on Autonomic and Peripheral Neuropathy in Patients With Diabetes Mellitus

Diabetic Autonomic Neuropathy Clinical Trial

Official title:

Efficacy of Administration of Angiotensin Converting Enzyme Inhibition on Autonomic and Peripheral Neuropathy in Patients With Diabetes Mellitus

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03031834
• Other study ID #: AristotleUMEDSCH095
• Status: Completed
• Phase: Phase 4
• First received: January 12, 2017
• Last updated: January 24, 2017
• Start date: January 1999

Study information

• Verified date: January 2017
• Source: Aristotle University Of Thessaloniki
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Patients with diabetes mellitus and definite autonomic and peripheral neuropathy were randomized to receive quinapril or no treatment for 2 years.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 0
• Est. primary completion date: May 2001
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Diabetes mellitus with both autonomic and peripheral neuropathy

Exclusion Criteria:

• Hypertension, coronary heart disease

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetic Autonomic Neuropathy
• Diabetic Neuropathies
• Peripheral Nervous System Diseases

Intervention

Drug:
• Quinapril

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Aristotle University Of Thessaloniki

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in R-R variation during deep breathing		2 years
Primary	Changes in response to Valsalva maneuver		2 years
Primary	Changes in 30:15 ratio		2 years
Primary	Changes in blood pressure response to standing		2 years